Dupixent shows potential as a treatment for atopic dermatitis, alopecia and vitiligo, targeting shared immune pathways for ...

Integrative approaches targeting neurological and immune pathways may help break the itch–scratch cycle in atopic dermatitis, improving pruritus, stress, sleep, and patient outcomes.

Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that it has entered into an exclusive strategic partnership with ...

Apogee Therapeutics recently reported positive 16-week results from its APEX Phase 2 Part A trial, with APG777 meeting all primary and key secondary endpoints in moderate-to-severe atopic dermatitis ...

Children with moderate/more extensive atopic dermatitis treated with ruxolitinib cream achieved significant disease control ...

A larger thymus size at 2 months of age is linked to an increased likelihood of having atopic dermatitis within the first 2 ...

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation is conducting a Phase 3b clinical ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 1 clinical trial titled ‘A PHASE 1, ...

For patients with skin of color and atopic dermatitis (AD), lebrikizumab is efficacious and safe, according to a study ...

Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, ...

If you experience chronic dry, itchy and red skin, you may be one of the millions of Americans with eczema. The National Eczema Association reports that an estimated 10% of the world ...

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.